Published Paper Details:

Streptomyces hygroscopicus produces rapamycin, a macrocyclic polyketide having immunosuppressive, antifungal, and anti-tumor activity. Rapamycin has made a substantial contribution to medicine. The wild strain's ability to produce, however, is quite limited. In this way, a computationally guided biotechnology technique was suggested to increase the production capacity of rapamycin. Based on its annotated genome and biochemical data, a metabolic model of Streptomyces hygroscopicus was built at the genome scale. Phylogenetic analysis of the 16S rRNA gene and genome sequences revealed that this strain unambiguously belonged to the genus Streptomyces Hygroscopicus, and its genomic features and functional genes were comprehensively analyzed and annotated. The core structure of rapamycin is derived from (4R, 5R)-4, 5-dihydrocyclohex-1-ene-carboxilic acid that is extended by polyketide synthase. Submerged fermentation is used by many strains of Streptomyces hygroscopicus to produce rapamycin. Due to the limited amount of medicine produced by the species, engineers confront a tremendous challenge in further developing and industrializing this essential polyketide. As a result, biotechnological manipulations are required for enhanced production of this critical antibiotic. The purpose of the current work was to describe the procedures for enhancing Streptomyces hygroscopicus species ability to synthesize rapamycin (Rap). Both UV radiation and N-methyl-N-nitro-N-nitrosoguanidine (NTG) have been employed as physical and chemical mutagens to increase rapamycin production. When rapamycin production is enhanced utilizing a sequential UV mutagenesis technique. It makes a significant difference to have access to a commercially viable amount of this important macrolide molecule. The present findings confirmed that various phylogenetically different streptomycetes strains produce rapamycin.